ERBB2 and triple-negative breast carcinoma: Studies based on microarray-based gene expression profiling have confirmed and validated the pathogenic role of hormone receptors (luminal tumors) and of the HER2 oncogene (HER2-positive enriched tumors), and the existence of so-called triple-negative breast cancers (TNBCs), which neither express ERα, PR and HER2, nor depend on their oncogenic pathways [7, 11].